10-Q: Qualis Innovations Reports Q2 2024 Results: Minimal Operating Activity and Continued Focus on Future Growth

Qualis Innovations reports no revenue for Q2 2024, focusing on development and future fundraising to support operations.

Summary

• Qualis Innovations, Inc. released its financial results for the quarter ended June 30, 2024.
• The company reported no net revenues for both the three and six months ended June 30, 2024 and 2023.
• Net loss for the three months ended June 30, 2024 was $31,228, compared to a net loss of $1,639,861 for the same period in 2023.
• Net loss for the six months ended June 30, 2024 was $47,388, compared to a net loss of $1,719,672 for the same period in 2023.
• Operating expenses decreased significantly, primarily due to lower stock-based compensation costs.
• As of June 30, 2024, the company's assets totaled $63,456, primarily consisting of cash.
• Liabilities totaled $33,800, including accounts payable, accrued expenses, and a short-term note payable.
• The company has an accumulated deficit of $4,477,696 as of June 30, 2024.
• Management intends to raise additional funds through a public offering or asset sale.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.

Sentiment

Score: 3

Explanation: The sentiment is low due to the lack of revenue, accumulated deficit, and going concern uncertainty, despite efforts to reduce operating expenses and seek additional funding.

Positives

• The company significantly reduced its net loss and operating expenses compared to the same periods in the previous year.
• The company's acting CEO and Chairman certified that the report fairly presents the company's financial condition and results of operations.
• The company is actively seeking additional funding through a public offering or asset sale.

Negatives

• The company reported no net revenues for the periods ended June 30, 2024 and 2023.
• The company has an accumulated deficit of $4,477,696 as of June 30, 2024.
• The company's auditors and the audit committee were informed of significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting.
• The company's disclosure controls and procedures were not effective to enable the company to accurately record, process, summarize and report certain information required to be included in the company's periodic SEC filings within the required time periods.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional funds or generate revenues.
• The company's cash position may not be sufficient to support its daily operations.
• The company has a limited operating history and has not finalized development of its planned SOLACE device.
• The company's disclosure controls and procedures were not effective to enable the company to accurately record, process, summarize and report certain information required to be included in the company's periodic SEC filings within the required time periods.
• The company's auditors and the audit committee were informed of significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting.

Future Outlook

The company intends to raise additional funds by way of a public offering or an asset sale transaction to support its operations and future growth.

Management Comments

• Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern.
• Management intends to raise additional funds by way of a public offering.

Industry Context

The company operates in the pain management and central nervous system (CNS) solutions sector, focusing on acquiring or developing existing devices that larger companies may have phased out.

Comparison to Industry Standards

• It is difficult to compare Qualis Innovations to industry standards due to its early stage and lack of revenue.
• Many companies in the medical device industry, such as Medtronic, Boston Scientific, and Abbott Laboratories, have established revenue streams and diverse product portfolios, which Qualis Innovations currently lacks.
• Smaller, clinical-stage companies often rely on venture capital or strategic partnerships to fund their operations until they can generate revenue from their products.

Related Party Transactions

• The Company borrows funds from the Company's CEO for working capital purposes from time to time.
• In January 2024, the Company issued 2,000,000 common shares to two (2) affiliates for aggregate gross proceeds of $100,000.
• In January 2024, the Company issued a total of 10,000,000 common shares valued at $500,000 (based on the estimated fair value of the stock on the date of grant) to two affiliates in settlement of a dispute.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial condition and need for additional funding.
• Employees' job security is uncertain due to the company's going concern risk.
• The company's ability to develop and market its SOLACE device is uncertain, impacting potential customers seeking pain management solutions.
• Creditors face risk of non-payment if the company is unable to raise additional funds or generate revenue.

Next Steps

• The company intends to raise additional funds by way of a public offering or an asset sale transaction.
• The company is trying to resolve a disagreement with a vendor about achieving a particular milestone, which they expect to be completed later in fiscal 2024.

Key Dates

Keywords

Qualis Innovations, financial results, Q2 2024, net loss, operating expenses, going concern, SOLACE device, share issuance, warrants, fundraising